Barclays Miami: enGene is looking to have pivotal data and to file for its non-viral delivered gene therapy for bladder cancer this year
CEO Ron Cooper describes why you need an alternative to virally delivered products for indications like bladder cancer. Plus, previewing a data update in the spring and 12 month data by the end of the year.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.